A step forward in the AIDS vaccine dance
The week began with a setback: a report that a planned $80 million trial of a promising vaccine, Aventis Pasteur's ALVAC, had been scrapped. The experiment wasn't dropped because the vaccine's a
The week began with a setback: a report that a planned $80 million trial of a promising vaccine, Aventis Pasteur's ALVAC, had been scrapped. The experiment wasn't dropped because the vaccine's a